The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Genetic alterations and signaling pathways in the evolution of gliomas
Abstract
Gliomas are the most common primary brain tumors. They account for more than 70% of all neoplasms of the central nervous system and vary considerably in morphology, location, genetic alterations, and response to therapy. Most frequent and malignant are glioblastomas. The vast majority (>90%) develops rapidly after a short clinical history and without evidence of a less malignant precursor lesion (primary or de novo glioblastoma). Secondary glioblastomas develop more slowly through progression from low‐grade or anaplastic astrocytoma. These glioblastoma subtypes constitute distinct disease entities that affect patients of different age, develop through distinct genetic pathways, show different RNA and protein expression profiles, and may differ in their response to radio‐ and chemotherapy. Recently, isocitrate dehydrogenase 1 (IDH1) mutations have been identified as a very early and frequent genetic alteration in the pathway to secondary glioblastomas as well as that in oligodendroglial tumors, providing the first evidence that low‐grade astrocytomas and oligodendrogliomas may share common cells of origin. In contrast, primary glioblastomas very rarely contain IDH1 mutations, suggesting that primary and secondary glioblastomas may originate from different progenitor cells, despite the fact that they are histologically largely indistinguishable. In this review, we summarize the current status of genetic alterations and signaling pathways operative in the evolution of astrocytic and oligodendroglial tumors. (Cancer Sci 2009; 100 2235–2241)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glioblastoma is associated with a number of mutations at the genomic level including mutations in the PTEN tumor suppressor and amplification of the gene encoding the epidermal growth factor receptor (EGFR) [3], [4].”
From Reduced Expression of Brain-Enriched microRNAs in Glioblastomas Permits Targeted Regulation of a Cell Death Gene (2011) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Repair of O6-alkylguanine by alkyltransferases
Pegg, A. E. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00017-x · Cited by 576 · cited 1×
“DNA methyltransferase (MGMT) is a repair protein that specifically removes promutagenic alkyl groups from O6-methylguanine,( 77 ) a promutagenic DNA adduct that causes G:C fi A:T mutations during DNA replication.(78,79) Loss or reduction of MGMT activity due to promoter methylation is frequent (40‐57%) in glioblastoma…”
BackgroundOkamoto, Y., Di Patre, P.-L., Burkhard, C., Horstmann, S., Jourde, B., Fahey, M., Schüler, D., Probst-Hensch, N. M., Yasargil, M. G., Yonekawa, Y., et al. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0861-z · Cited by 330
Self-citation
Flagged first, then by citations
Research works printed but not linked: 82
- Louis DN, 2007, WHO Classification of Tumours of the Central Nervous System
- 10.1158/0008-5472.CAN-04-1337 · DOI
- 10.1093/jnen/64.6.479 · DOI
- 10.2353/ajpath.2007.070011 · DOI
- 10.1097/WCO.0b013e3280895da8 · DOI
- 10.1073/pnas.89.10.4309 · DOI
- 10.1111/j.1750-3639.1996.tb00848.x · DOI
- 10.1097/00005072-199807000-00005 · DOI
- 10.1111/j.1750-3639.2004.tb00045.x · DOI
- 10.1074/jbc.272.5.2927 · DOI
- 10.1215/15228517-4-3-196 · DOI
- 10.1007/s00401-006-0186-1 · DOI
- Hermanson M, 1992, Platelet‐derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops, Cancer Res, 52, 3213
- Reifenberger J, 1996, Epidermal growth factor receptor expression in oligodendroglial tumors, Am J Pathol, 149, 29
- 10.1097/00006123-199802000-00080 · DOI
- 10.1002/glia.440150311 · DOI
- 10.1101/gad.13.12.1501 · DOI · Paper page
- 10.1093/emboj/17.17.5001 · DOI
- 10.1101/gad.8.15.1739 · DOI · Paper page
- 10.1093/nar/23.14.2584 · DOI · Paper page
- 10.1016/j.biocel.2007.03.022 · DOI · Paper page
- 10.1111/j.1750-3639.2001.tb00388.x · DOI
- 10.1097/00005072-199702000-00009 · DOI
- Reifenberger G, 1993, Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations, Cancer Res, 53, 2736
- 10.1111/j.1750-3639.2008.00170.x · DOI
- 10.1093/jnen/60.12.1181 · DOI
- 10.1007/s004010050711 · DOI
- 10.1007/BF00295665 · DOI
- Devlin TM, 2006, Textbook of Biochemistry with Clinical Correlations
- 10.1074/jbc.274.43.30527 · DOI
- 10.1007/s00401-008-0455-2 · DOI · Paper page
- 10.2353/ajpath.2009.080958 · DOI · Paper page
- 10.1002/humu.20937 · DOI
- Rasheed BK, 1995, Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25, Oncogene, 10, 2243
- 10.1007/BF00219686 · DOI
- 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1 · DOI
- 10.1038/labinvest.3780009 · DOI
- Fults D, 1998, Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme, Int J Oncol, 12, 905
- 10.1038/sj.bjc.6693403 · DOI
- 10.1016/S0002-9440(10)61702-6 · DOI
- 10.1093/jnen/59.6.539 · DOI
- 10.1054/bjoc.1999.0961 · DOI
- 10.1073/pnas.0900571106 · DOI
- 10.1158/0008-5472.CAN-08-3272 · DOI
- 10.1038/labinvest.3700223 · DOI
- 10.1093/jnci/90.19.1473 · DOI
- 10.1016/S0360-3016(00)00703-3 · DOI
- 10.1111/j.1750-3639.2004.tb00044.x · DOI
- 10.1158/0008-5472.CAN-06-1796 · DOI
- 10.1002/gcc.2870050411 · DOI
- 10.1002/ijc.2910570207 · DOI
- 10.1002/1098-2264(2000)9999:9999<::AID-GCC1007>3.0.CO;2-I · DOI
- 10.1016/j.cancergencyto.2004.11.012 · DOI
- 10.1200/JCO.2000.18.3.636 · DOI
- 10.1200/JCO.2005.04.3414 · DOI
- 10.3171/jns.2000.92.6.0983 · DOI
- 10.1097/01.jnen.0000235118.75182.94 · DOI
- 10.1097/00005072-199803000-00005 · DOI
- 10.1002/ijc.21648 · DOI
- Godard S, 2003, Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes, Cancer Res, 63, 6613
- 10.1158/0008-5472.CAN-05-0077 · DOI
- 10.1158/1078-0432.CCR-07-4821 · DOI
- 10.1038/sj.onc.1208865 · DOI
- 10.1038/sj.onc.1207770 · DOI
- Huang H, 2000, Gene expression profiling of low‐grade diffuse astrocytomas by cDNA arrays, Cancer Res, 60, 6868
- 10.1158/0008-5472.CAN-06-0127 · DOI
- 10.1200/JCO.2007.11.8554 · DOI
- 10.1093/mutage/17.6.483 · DOI
- 10.1159/000077469 · DOI
- 10.1056/NEJMoa043331 · DOI · Paper page
- 10.1056/NEJM200011093431901 · DOI
- 10.1159/000170088 · DOI
- 10.1158/1078-0432.CCR-04-0392 · DOI
- 10.1007/s11060-006-9320-0 · DOI
- 10.1158/1078-0432.CCR-06-2149 · DOI
- 10.1158/0008-5472.CAN-06-4180 · DOI
- 10.1038/nature05236 · DOI
- 10.1186/1476-4598-5-67 · DOI
- Singh SK, 2003, Identification of a cancer stem cell in human brain tumors, Cancer Res, 63, 5821
- 10.1038/nature03128 · DOI
- 10.1038/labinvest.2008.57 · DOI
- 10.1371/journal.pone.0003655 · DOI
Cited by
Sorted by citations
Reitman, Z. J., & Yan, H. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq187 · Cited by 562
Jhanwar-Uniyal, M., Wainwright, J. V., Mohan, A. L., Tobias, M. E., Murali, R., Gandhi, C. D., & Schmidt, M. H. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.03.003 · Cited by 268
Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222
Skalsky, R. L., & Cullen, B. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024248 · Cited by 170
Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor
Costa, B., Bendinelli, S., Gabelloni, P., Da Pozzo, E., Daniele, S., Scatena, F., Vanacore, R., Campiglia, P., Bertamino, A., Gomez-Monterrey, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072281 · Cited by 79
Metadata
- Authors
- Ohgaki, H., & Kleihues, P.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2009-11-11
- Volume
- 100
- Issue
- 12
- Pages
- 2235-2241
- ISSN
- 1347-9032
- 1349-7006
- Cited by
- 355
- References
- 10
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
